A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,301–3,400 of 3,966
Weniger Hospitalisierung aus respiratorischen Gründen bei IPF mit Pirfenidon
Markart, P., & Günther, A. (2017) · Pneumo News · doi:10.1007/s15033-017-0723-8
Treatment of Pulmonary Hypertension in Interstitial Lung Disease
King, C. S., & Nathan, S. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_4
Self-citationTanizawa, K., Collard, H. R., & Ryerson, C. J. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10015916
Pharmakologische und nicht-pharmakologische Therapie der idiopathischen Lungenfibrose
Schertel, A., Funke-Chambour, M., & Geiser, T. (2017) · Praxis · doi:10.1024/1661-8157/a002770
Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis
Sgalla, G., & Richeldi, L. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.08.005
Seeing Deeply into the Lung in Interstitial Lung Disease
Kaner, R. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1798ed
Exogen-allergische Alveolitis — ein weiterhin aktuelles Thema
Knoop, U., & Knoop, H. (2017) · Pneumo News · doi:10.1007/s15033-017-0760-3
Novel approaches to identify biomechanisms in systemic sclerosis
Lopez, H. (2017) · UCL Discovery (University College London)
An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis
Ohshimo, S., Costabel, U., & Shime, N. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.12.003
Idiopathic Pulmonary Fibrosis: Treatment Strategies
Varela, B. E., & Tabaj, G. C. (2015) · Clinical Anti-Inflammatory & Anti-Allergy Drugs · doi:10.2174/221270380102150520112938
Zyryanov, S. K., Butranova, O. I., & Shatalova, O. V. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-6-789-802
Therapeutic Strategies for Interstitial Lung Diseases in Rheumatoid Arthritis
Suda, T. (2018) · Springer eBooks · doi:10.1007/978-981-10-6750-1_9
Traitement de la fibrose pulmonaire idiopathique : un espoir pour les connectivites
Wémeau-Stervinou, L., Chenivesse, C., & Wallaert, B. (2018) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2018.03.003
Schaeffer, M. R. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0364703
Experten-Empfehlungen zur transbronchialen Kryobiopsie
Gesierich, W. (2018) · Pneumo News · doi:10.1007/s15033-018-0882-2
Crossing points in survival analysis sensitively depend on system conditions.Preprint
McAndrew, T., Redfors, B., Zhang, Y., Crowley, A., Chen, S., Stone, G., & Jenkins, P. L. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1805.02835
Szturmowicz, M., Kacprzak, A., & Kuś, J. (2018) · Advances in respiratory medicine · doi:10.5603/arm.57075
It takes a village to care for the patient with idiopathic pulmonary fibrosis
Fischer, A. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17117
Spanish Society of Caridiorespiratory Rehabilitation. Recommendations in Lung Transplantation
Solchaga, M. R., Fernadez, C. A., Monteagudo, L. J., Cabello, L. M., Mir, R., Arce, I. V., & Lopez, S. G. (2018) · International Journal of Physical Medicine & Rehabilitation · doi:10.4172/2329-9096.1000459
Therapeutic approach and molecular targets for novel treatments
Sgalla, G., Jones, M. G., & Richeldi, L. (2015) · doi:10.2217/fmeb2013.14.74
Lee, J. S., & Fontenot, A. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00072-7
Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis
Ho, L. A., & Raghu, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-90525-9_16
[Hemodynamic effects of disopyramide and procainamide in open-chest animals].
Binetti, G. G., Branzi, A., Malini, P. L., Specchia, S., Magelli, C., Zannoli, R., & Magnani, B. (1978) · PubMed
Pretransplant Considerations in Patients with Pulmonary Fibrosis
Carbone, R. G., Monselise, A., Wille, K. M., Bottino, G., & Puppo, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-91184-7_4
Lung Allograft Dysfunction (LAD) and Bronchiolitis Obliterans Syndrome
Vanaudenaerde, B. M., Vos, R., Verleden, S. E., Vandermeulen, E., & Verleden, G. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-91184-7_16
Diffuse Parenchymal Lung Diseases in the Elderly
Walsh, S. M., & O'Regan, A. W. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0249-x
Who and When to Transplant: What Has Changed?
Seneviratne, I. N. S., & Hopkins, P. M.-A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_1 · Cited by 2
Self-citationLung Transplantation for Interstitial Lung Disease
Malouf, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_12
Lung Transplantation in Interstitial Lung Disease
Paoletti, L., & Whelan, T. P. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00009-4
Aktuelle Aspekte der Lungentransplantation
von Samson-Himmelstjerna, P. (2018) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/s-0043-110180
Natural History of Idiopathic Pulmonary Fibrosis and Disease Monitoring
Sergew, A., & Brown, K. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00009-3
Pérez, E. R. F., Amigues, I., & Solomon, J. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00008-1
Respiratory Organ Aging and Cancer
Witt, L. J., & Presley, C. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_63-1
Connective Tissue Related Interstitial Lung Disease
Gadre, A., & Highland, K. B. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0212-5 · Cited by 1
Pirfénidone (Esbriet®) : attention au soleil !
Schmutz, J. L. (2018) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2018.09.002
EXPERIENCE OF NINTEDANIB USE IN THE PATIENT WITH IDIOPATHIC PULMONARY FIBROSIS AND EMPHYISEMA
Kudelya, L. M., Manakova, Y. L., & Khusainova, Е. S. (2018) · Siberian medical review · doi:10.20333/2500136-2018-5-99-103
Considerable Therapeutic Strategies for Treatment of Genetic Defects Govern Neurovascular Disease
Chaudagar, K. K., & Kanwal, A. (2018) · Ecoproduction · doi:10.1007/978-3-319-92399-4_16
The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis
Shimbori, C., Upagupta, C., Forsythe, P., & Kolb, M. R. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_6
Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis
Buendía-Roldán, I., Mejía, M. E., & Selman, M. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2018.09.018
Fibrosis and Immune Dysregulation in Systemic Sclerosis
Argobi, Y., & Smith, G. P. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_2 · Cited by 2
Antifibrotics: Shrinking the Box of Therapeutic Uncertainty
Guler, S. A., & Funke-Chambour, M. (2018) · Respiration · doi:10.1159/000494275
IDIOPATHIC PULMONARY FIBROSIS. CORRECTION OF ERRORS
Yudin, A., Abovich, Y. A., & Афанасьева, Н. И. (2018) · Journal of radiology and nuclear medicine · doi:10.20862/0042-4676-2018-99-5-269-278
Future Directions for IPF Research
Craig, J. M., Aggarwal, N. R., & Kiley, J. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_20
Gastroesophageal Reflux and IPF
Lee, J. S. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_15 · Cited by 1
Bouvry, D. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30049-1 · Cited by 1
Cardiovascular risk in Idiopathic Pulmonary Fibrosis
Thillai, M. (2018) · International Journal of Pulmonary & Respiratory Sciences · doi:10.19080/ijoprs.2018.03.555623
3) Pulmonary Fibrosis and Its Management
Azuma, A. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.2183
Biomarker discovery and drug testing in Idiopathic Pulmonary Fibrosis
Fernandez, I. E. (2018) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.23287
Determinants of Dyspnea Associated with Pleural Effusion
Garske, L. A. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122900
Exercise in Interstitial Lung Diseases
Vainshelboim, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-05258-4_7
Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis
Tzilas, V., Tzouvelekis, A., & Bouros, D. E. (2019) · Respiration · doi:10.1159/000497391
Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis
Chung, A., English, J., & Volkmann, E. R. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00121-1
Fibrosis and Stricturing Disease in Crohn’s Disease
Kurada, S. V., & Rieder, F. (2019) · Springer eBooks · doi:10.1007/978-3-030-11446-6_7
Fibrose rénale: peut-elle être traitée ?
Kormann, R., Chadjichristos, C. E., & Chatziantoniou, C. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30461-3 · Cited by 1
Fibrose pulmonaire idiopathique : progrès étiologiques, diagnostiques, et thérapeutiques
Cordier, J.-F. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31230-0
Clinical Meaning of Transbronchial Cryobiopsy
Puglisi, S., Ravaglia, C., Arcadu, A., Tomassetti, S., & Poletti, V. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-14891-1_10
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévôt, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.020 · Cited by 1
Identifying “Real” Patients in the Real World
Callahan, S. J. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201907-1458le
Kumar, P., & Hood, M. (2019) · International Journal Of Medical Science And Clinical Invention · doi:10.18535/ijmsci/v6i9.06
Urinary Proteome Biomarkers for Early Detection of Respiratory Diseases
Wu, J., & Huang, H. (2019) · Springer eBooks · doi:10.1007/978-981-13-9109-5_13
Idiopathic Pulmonary Fibrosis-Treatment and Management
Collins, B. F., & Raghu, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11455-2
The Role of the Ovarian Cancer G -Coupled Receptor (OGR1) in Idiopathic Pulmonary FibrosisPreprint
Nagel, D. J., Clough, R., Bell, T. J., Ku, W.-Y., Sime, P. J., & Kottmann, R. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/849117 · Cited by 1
“Pooled data from the INPULSIS and TOMORROW trials involving nintedanib demonstrated a reduction in acute exacerbations[59] and secondary endpoint analysis with pirfenidone and nintedanib suggest an improvement in all-cause and IPF related mortality[60, 61].”
ResultMedizin, S. (2019) · Pneumo News · doi:10.1007/s15033-019-1330-7
Antifibrotische Therapie der idiopathischen pulmonalen Fibrose
Markart, P., Drakopanagiotakis, F., & Wygrecka, M. (2020) · Der Pneumologe · doi:10.1007/s10405-019-00296-3
Pereira, D. A. S. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-29012020-115137
Beyond standard care?—idiopathic pulmonary fibrosis patients’ perception of care coordinators
Hagmeyer, L., & Randerath, W. J. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.40
Morphological and functional studies in a sheep model of pulmonary fibrosis
Dewage, V., & Nimanthi, S. (2020) · Minerva Access (University of Melbourne)
Modern approach to therapy of patients with idiopathic pulmonary fibrosis
Oa, T., Олеговна, В. О., & Евгеньевна, Б. О. (2017) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2017-95-3-281-285
Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
Sgalla, G., & Richeldi, L. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20200193
Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?
Spek, C. A., & Duitman, J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00811-2020 · Cited by 2
Weissferdt, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-36438-0_3
WILSHER, M. L., & Beckert, L. (2020) · Respirology · doi:10.1111/resp.13906
Gianni, B. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.28.004598
New developments in respiratory medicine: a primary immunodeficiency perspective
Ng, K. L., & Hurst, J. R. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000690
Pirfenidone Experience in Idiopathic Pulmonary Fibrosis at a Tertiary Hospital in Oman
Busaidi, N. A. (2020) · Journal of Thoracic Disease and Cardiothoracic Surgery · doi:10.31579/2693-2156/001
“S and his colleagues showed that the mean of FVC before starting Pirfenidone was 80%.”
BackgroundMethodResultInfluentialUse of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis
Chakraborty, A., & Royce, S. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00005-4 · Cited by 1
Bhole, R. P., Jagtap, S. R., Bonde, C. G., et al. (2020) · Bulletin of the Karaganda University Chemistry series · doi:10.31489/2020ch3/51-60
Idiopatinės plaučių fibrozės diagnostikos ir gydymo rekomendacijos 2017
Malakauskas, K., Biekšienė, K., Dobrovolskienė, L., Miliauskas, S., Šarauskas, V., Zaveckienė, J., & Žemaitis, M. (2017) · Pulmonology and allergology · doi:10.37499/pia.207
Pirfenidono veiksmingumas ir saugumas gydant idiopatinę plaučių fibrozę
Blažytė, L., & Malakauskas, K. (2016) · Pulmonology and allergology · doi:10.37499/pia.278
Goodwin, A. T., & Saini, G. (2020) · Breathe · doi:10.1183/20734735.0066-2020
Pirfenidono klinikinio veiksmingumo metaanalizė, gydant idiopatinę plaučių fibrozę
Kalinauskaitė-Žukauskė, V. (2017) · Pulmonology and allergology · doi:10.37499/pia.218
Infecciones y esclerosis sistémica: un desafío emergente
Correa, J. E. B., la Hoz, A. D., López, M. J., Garzón, J., Allanore, Y., & Quintana‐López, G. (2020) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2019.12.007 · Cited by 3
Valtchinov, V. I., Seo, J. B., Hida, T., & Hatabu, H. (2020) · Medical radiology · doi:10.1007/978-3-030-43539-4_15
The loss of IL-31 signaling attenuates bleomycin-induced pulmonary fibrosisPreprint
Yombo, D. J. K., Odayar, V., Gupta, N., Jegga, A. G., & Madala, S. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423450
Treatment of systemic sclerosis-associated interstitial lung disease: a work in progress
Oldham, J. M. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30458-6
A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis
Kolaitis, N. A., & Shah, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00080-9
The Promise (and Pitfalls) of Administrative Data for Idiopathic Pulmonary Fibrosis
Fisher, J. H. (2021) · CHEST Journal · doi:10.1016/j.chest.2020.09.241
Villeneuve, T., Prévôt, G., Lintz, F., Mourin, G., Ferry, G., Bousquet, E., Perelroizen, H., Boghanim, T., Faviez, G., Noël-Savina, É., et al. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/j.rmra.2020.11.055
Tetrandrine modulates SQSTM1-mediated selective autophagy and protects pulmonary fibrosisPreprint
Liu, Y., Zhong, W., Zhang, J., Chen, W., Lu, Y., Qiao, Y., Zeng, Z., Huang, H., Zou, F., Meng, X., et al. (2021) · doi:10.22541/au.161185451.12306983/v1
ERS International Congress 2020: highlights from the Thoracic Surgery and Transplantation Assembly
Esendagli, D. R., Shah, U. B., Batıhan, G., Magouliotis, D. E., Meloni, F., Vos, R., Elia, S., & Hellemons, M. E. (2021) · ERJ Open Research · doi:10.1183/23120541.00743-2020
Fisher, J. H. (2017) · TSpace (University of Toronto)
Zheng, Y. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3428
Lang, D., Moazedi‐Fürst, F., Sautner, J., Prosch, H., Handzhiev, S., Hackner, K., Tancevski, I., Flick, H., Koller, H., Kiener, H. P., et al. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01874-3
Targeting hepatic stellate cells to prevent or reverse liver fibrosis
Zhang, M. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.146692010
Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen
Föll, D., & Kallinich, T. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-60411-3_24-1
Sarcoidosis: An FP’s primer on an enigmatic disease
Gupta (2021) · The Journal of Family Practice · doi:10.12788/jfp.0177
Clinical Applications of High-Flow Nasal Cannula in Pulmonary Rehabilitation
Poli, B. F., Lastoria, C., & Carlucci, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-42454-1_8
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2021) · Research Square · doi:10.21203/rs.3.rs-729282/v1
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.